AI Financial Corp (AIFC) Expected Move

Tracking the AIFC expected move helps you see how far AI Financial Corp's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. AI Financial Corp's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the AIFC expected move for this week's options, in real time.

The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For AIFC, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The AIFC expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks AI Financial Corp is unlikely to go.

AI Financial Corporation, a global entity operating through its various subsidiaries, specializes in distributed ledger technology solutions. The company's activities are strategically divided into two primary segments: Fintech and Biotechnology. Its Fintech division manages the entire ecosystem of digital assets, covering everything from their initial creation (tokenization) to their trading, clearing, settlement, payment processing, and secure safekeeping. Within this sector, AI Financial offers significant products such as ALT 5 Prime, a sophisticated electronic over-the-counter (OTC) trading platform designed for the acquisition and divestiture of digital assets.

Another key offering is ALT 5 Pay, a cryptocurrency payment gateway that empowers merchants to either accept and disburse payments in digital currencies directly or integrate this capability into their existing software applications. The biotechnology arm is dedicated to identifying, procuring, licensing, advancing, collaborating on, and commercializing innovative, non-opioid, and non-addictive therapeutic solutions for addressing pain and addiction. Noteworthy projects include JAN 101, an orally administered, sustained-release sodium nitrite compound that has successfully concluded Phase 2a clinical trials for the treatment of peripheral arterial disease and pain. Additionally, the company is developing JAN123, a low-dose naltrexone formulation specifically tailored for managing chronic regional pain syndrome. Established in 1976, the company is based in Las Vegas, Nevada. It officially adopted its current name, AI Financial Corporation, in April 2026, having previously been known as ALT5 Sigma Corporation.

Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the AIFC expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The AI Financial Corp expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about AIFC.